@KRASKickers

#KRAS 🎯cancer patient group for reliable Knowledge Research Advocacy & Survivorship. Survival of the strategic. #KickCancersKRAS - 🚫 #KRASholes

 International, ALL RAS cancers
kraskickers.org
Joined February 2020
  • Tweets5.1K
  • Following4.9K
  • Followers4.2K
551Media
At @ASCO #GI26 we presented our KRAS KICKERS Trial Finder. Personalized: KRAS G12D, CRC, US trials Results (in 4 minutes): 20 trials go to KRASHUB.ORG in beta - would love your feedback abstract asco.org/abstracts-presentat… FYI: G12V - 8 trials for CRC G12R - 7 trials for CRC
3
3
1
10
3,804
#ESMO26 KRAS G12C
Business-News-Today.com
@BNTBriefingOct 20
Frontier to reveal first FMC-376 clinical responses in KRAS G12C lung cancer pharmadevicenews.com/frontie… @FrontierMeds will disclose the first human data for FMC-376 on October 25, including tumor responses in patients previously treated with KRAS G12C inhibitors. Unlike established OFF-state inhibitors, FMC-376 is designed to target both active and inactive KRAS G12C. The key question is whether this dual mechanism can produce durable responses without unacceptable toxicity. #FrontierMedicines #FMC376 #ESMO2026 #KRASG12C #LungCancer #NSCLC #PrecisionOncology #TargetedTherapy #ClinicalTrials #Biotechnology

Frontier to reveal first FMC-376 clinical responses in KRAS G12C lung cancer

Frontier Medicines, a privately held biotechnology company operating in Boston and South San Francisco, announced on October 16, 2026, that it will present the first clinical results for FMC-376, its...

pharmadevicenews.com
1
4
425
Frontier to reveal first FMC-376 clinical responses in KRAS G12C lung cancer pharmadevicenews.com/frontie… @FrontierMeds will disclose the first human data for FMC-376 on October 25, including tumor responses in patients previously treated with KRAS G12C inhibitors. Unlike established OFF-state inhibitors, FMC-376 is designed to target both active and inactive KRAS G12C. The key question is whether this dual mechanism can produce durable responses without unacceptable toxicity. #FrontierMedicines #FMC376 #ESMO2026 #KRASG12C #LungCancer #NSCLC #PrecisionOncology #TargetedTherapy #ClinicalTrials #Biotechnology

Frontier to reveal first FMC-376 clinical responses in KRAS G12C lung cancer

Frontier Medicines, a privately held biotechnology company operating in Boston and South San Francisco, announced on October 16, 2026, that it will present the first clinical results for FMC-376, its...

pharmadevicenews.com
1
1
2
527
Just seen at #ESMO26 RAS Biology session with Professor Chiara Abrogrio @AmbrogioLab
Bjoern Papke@papkephdAug 27
Replying to @nytimes
@nytimes cited my webpage rasinhibitors.com as the source for the number of RAS inhibitors in active clinical development, in today's article on what follows the daraxonrasib approval. rasinhibitors.com #RAS #TargetedTherapy

RAS Inhibitors in Clinical Development

A curated overview of RAS inhibitors in clinical development.

rasinhibitors.com
2
15
1,155
KRAS Kickers retweeted
Anirban Maitra@Aiims1742Oct 24
So ready for the NCI p53 initiative!
The Cancer Letter
@TheCancerLetterOct 23
Kevan Shokat (@kevansf) made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53 Shokat was named 2026 Stephenson Global Prize winner cancerletter.com/conversatio…
8
12
1
156
13,531
#ESMO26 #ESMO2026 #JetLag #ESMOAmbassadors ⏰
🤖 Made with AI
3
302
KRAS Kickers retweeted
Anirban Maitra@Aiims1742Oct 23
Mechanism wise there has got to be a bi-directional crosstalk between wild type RAS and PRMT5 First Daraxonrasib has greater ORR than Zoldonrasib per press release, and second: “and partly because targeting PRMT5 may attenuate some of Rasonque’s toxicities”
3
2
10
1,397
KRAS Kickers retweeted
PDBrown
@PDBrownOncOct 5
Placebo Controlled Randomized Trial: Memantine given w/Brain RT Improved Cognitive Outcomes & QOL 1/3 sciencedirect.com/science/ar…
3
29
1
66
3,691
Today at #ESMO26: Zev Wainberg will present additional subgroup analyses from the phase 3 RASolute 302 study of daraxonrasib vs. chemotherapy in previously treated metastatic pancreatic adenocarcinoma. @MSKCancerCenter's @EileenMOReilly is the senior author. 📅 October 23 | 2:22 p.m. CEST
A promotional graphic featuring headshots of Zev Wainberg and Eileen O'Reilly and the presentation title and date.

ALT A promotional graphic featuring headshots of Zev Wainberg and Eileen O'Reilly and the presentation title and date.

1
3
14
536
KRAS Kickers retweeted
Grainne O'Kane
@graokaneOct 23
AMPLIFY-7P randomised ph2 ✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile ➡️curative intent & no recurrence <6mth #PDAC ✅T cell responses,primary endpt-ve ➡️benefit in ctDNA-ve& no rads? ➡️DFS @6mth benefit of 14% p=0.056 ✅ph3 planned @myESMO @OncoAlert #ESMO26
1
14
11
616
Zev Wainberg presents subgroup analyses from phase 3 RASolute 302 study of #daraxonrasib in patients with previously treated metastatic #PDAC at #ESMO26 (part 1) #ESMOAmbassadors @myESMO
6
6
319
KRAS Kickers retweeted
Arndt Vogel
@ArndtVogelOct 23
AMPLIFY-7P ph 2 study: Seven-valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected PDAC) #ESMO26 #ESMOAmbassadors 👉 Targeting lymph nodes to activate T-cells 👉T-cells response in 99% of pts 👉poor outcome in ctDNA pos pts 🧐promising data, specifically in pts with Tcell response @myESMO
1
13
17
1,085
KRAS Kickers retweeted
Grainne O'Kane
@graokaneOct 23
#LBA82 subgroup analysis RASolute 302 #PDAC ➡️HR for OS across subtypes 0.32-0.46 ➡️G12R 0.61 (0.29-1.30) ➡️RAS WT numbers small (3%) but still OS benefit! 🤔perhaps ORR and mPFS not as pronounced in these populations! ✅std second line treatment @myESMO #ESMO26 @OncoAlert
1
12
1
16
1,231
#ESMO26 🚀 RASolute 302 | Phase III 👥 500 pts | Previously treated mPDAC 💊 Daraxonrasib (RAS(ON) inhibitor) vs chemo 📈 OS: 13.2 vs 6.7 mo (HR 0.40) 🧬 OS benefit by RAS genotype: 🔹 G12D: HR 0.49 🔹 G12V: HR 0.32 🔹 G12R: HR 0.61 📊 PFS: HR 0.55 (BICR) 🎯 ORR: 32% vs 11% 💡 new SOC! @OncoAlert
1
37
1
71
6,407
Wow 🤩 #ESMO26 Plus 3 papers in @JCO_ASCO 💪 @myESMO @OncoAlert @Annals_Oncology @ESMO_Open @TheLancet @JAMA_current @TheLancetOncol @NEJM @Nature @NatureMedicine
2
10
1
23
2,023
Coming up at #ESMO26: MSK gastrointestinal medical oncologist @EileenMOReilly will present the AMPLIFY-7P randomized phase 2 study comparing an mKRAS-specific immunotherapy with observation in patients with resected pancreatic ductal adenocarcinoma. 🗓️ Friday, October 23 | 2:32 p.m. CEST
11
1
24
2,242
Join us at #ESMO26 for the "Advancing the Frontiers of Lung Cancer Care" symposium, where I will discuss KRAS, SCLC, immunotherapy, and ADCs with Dr. @FSkoulidis, Dr. Margarita Majem, and @TerriConneran. Monday, October 26, 13:00 CET, Oviedo Auditorium, Hall 5, IFEMA Madrid!
15
37
2,269
📍Don’t miss the lecture @myESMO #ESMO26 “Drugging the undruggables: The next wave of targeted therapies” @OncoAlert @oncodaily Link - cslide.ctimeetingtech.com/es…
4
2
12
1,651
#ESMO26
MeDucation
@MeDucationaiOct 21
Put @VivekSubbiah's #ESMO26 lecture on drugging the undruggables on your list. The pearl for fellows: KRAS G12C went from undruggable to approved by trapping the inactive GDP-bound state, and the next wave is going after the active RAS(ON) state instead.
1
5
503
Joining #UpperGIHPB2026 in Bengaluru virtually for the keynote, with the latest data from #ESMO: "Metastatic Pancreatic Cancer 2026: From Cytotoxicity to KRAS: Are We Finally Changing the Game?" 📅 Oct 31, 6:45 PM IST Thanks @ApolloCancerCentres & Dr. Vishwanath S!
1
1
202
KRAS Kickers retweeted
Open Medicine
@OpenMedicineHQOct 22
How to start dermatologic prophylaxis before first dose, Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and @GIcancerDoc:
2
7
10
552
Load more